Skip to content
Peptide Atlas
All peptides

PTD-DBM

Tier 3 · Reported use
Also known as PTD-DBM peptide · Protein transduction domain-Dvl-binding motif

Direct efficacy evidence is overwhelmingly preclinical — mouse models and cultured human dermal papilla cells. A tier-1 PubMed review (src-16) asserts clinical efficacy as a peptide therapeutic for hair growth, and lower-tier sources describe a small unregistered human study (Choi et al. 2017, n=34, per src-12) and a vendor-claimed Phase 1/2 trial (n=40, +28.4% hair count, per tier-4 src-4). However, most sources (src-1, src-3, src-5, src-6, src-9, src-10) state that as of 2026 no completed peer-reviewed human RCTs of PTD-DBM have been published. Given this conflict and the preclinical weight of the direct efficacy data, the tier is set at 2; the tier-1 review is present but its human-efficacy claim is contested. Note the PP405 phase 2A trial (src-14) concerns a different peptide, not PTD-DBM.

Half-life
~2 h
Routes
Topical · Microneedling-assisted topical · Subcutaneous injection (vendor-described)
Goals
Hair growth / androgenetic alopecia · Wound healing / tissue repair · Anti-scarring / skin regeneration
Cost / mg
Not recorded

How it works

Vendor and educational guides describe PTD-DBM as a synthetic peptide designed to switch a natural brake back off inside hair-follicle cells. According to these sources, the Wnt/beta-catenin pathway drives hair-follicle growth and regeneration, and a protein called CXXC5 normally acts as a brake on that pathway by binding to a signaling protein called Dishevelled (Dvl). PTD-DBM is described as carrying a Dvl-binding fragment into cells (using a cell-penetrating carrier segment) where it competes with CXXC5 for Dvl, freeing Dvl to reactivate Wnt signaling and, in mouse studies, stimulating hair regrowth and even the formation of new follicles. Sources note that in androgenetic alopecia the DHT→PGD2→CXXC5 axis raises CXXC5 and suppresses this pathway, and that PTD-DBM is proposed to reverse that suppression. Nearly all direct efficacy evidence to date comes from mice and cultured cells.

Overview

Overview

PTD-DBM (Protein Transduction Domain–Dvl-Binding Motif) is described by vendor and educational guides as a synthetic research peptide designed to block the CXXC5–Dishevelled (Dvl) interaction and disinhibit Wnt/beta-catenin signaling in hair follicles (src-1, src-2, src-3, src-6, src-7, src-9, src-10, src-11). One peptide profile explains that "PTD" refers to the protein transduction domain, which enables cellular entry across the stratum corneum, while "DBM" refers to the Dishevelled-binding motif that physically competes with CXXC5 for the Dvl PDZ domain (src-1).

Origin

Several sources report that PTD-DBM was developed by Professor Kang-Yell Choi's laboratory at Yonsei University in South Korea, with CXXC5 identified as a negative-feedback regulator of the Wnt/beta-catenin pathway by Kim and colleagues in 2015 (src-1, src-5). One profile describes it as a 25-amino-acid peptide containing an eight-arginine PTD sequence (RRRRRRRR) fused to a DBM segment (RKTGHQICKFRK), with CAS number 1609454-11-6 (src-5), and one vendor guide gives a molecular weight of approximately 2,500 Da (src-2). These molecular figures each come from a single low-tier vendor page.

Rationale

Educational sources note that Wnt/beta-catenin signaling is the dominant molecular pathway governing hair follicle development, regeneration, and cycling, and that inactivation of beta-catenin causes dramatically reduced proliferation of hair progenitor cells and premature entry into catagen (src-1, src-7). A 2007 Nature paper by Ito, Cotsarelis, and colleagues demonstrated that Wnt signaling can produce entirely new follicles in adult mouse skin after wounding (src-1). Vendor material describes that in androgenetic alopecia the DHT→PGD2→CXXC5 axis upregulates CXXC5, suppressing Wnt signaling and arresting follicle cycling, and that PTD-DBM is proposed to reverse this by restoring Dvl-mediated signaling (src-4, src-6).

Preclinical evidence

A 2015 study (PubMed 26056233) reported that CXXC5 serves as a negative-feedback regulator of Wnt/beta-catenin by binding Dvl, that CXXC5 protein levels were reduced in human acute-wound keratinocytes and fibroblasts, that CXXC5(-/-) mice showed accelerated cutaneous wound healing with enhanced keratin 14 and collagen synthesis, and that PTD-DBM disrupted the CXXC5-Dvl loop and activated beta-catenin and collagen production in vitro (src-18). A 2015 Journal of Experimental Medicine study reported that disrupting the CXXC5-Dvl interaction accelerated skin repair in mouse models (src-1, src-13).

The foundational 2017 mouse study, reported in the Journal of Investigative Dermatology (137(11):2260–2269), demonstrated visible hair regrowth and de novo follicle neogenesis in mice (src-1, src-11). Lee 2017 reported that PTD-DBM disrupted CXXC5-Dishevelled binding, restored Wnt/beta-catenin signaling, and stimulated hair regrowth and wound-induced hair neogenesis in mouse models (src-9). One profile reports that topical PTD-DBM alone produced visible hair regrowth in C57BL/6 mice at levels comparable to minoxidil (src-5), and another reports that topical PTD-DBM applied to shaved mouse skin induced new follicles from epidermal and dermal progenitor cells, histologically confirmed with proper dermal papilla organization, inner and outer root sheaths, and hair fiber production (src-8, src-11). In cultured human dermal papilla cells, one source reports PTD-DBM restored alkaline phosphatase activity and increased expression of versican, beta-catenin, and LEF-1 (src-8).

Animal studies report that combining PTD-DBM with valproic acid (a GSK-3beta inhibitor and Wnt activator) produced significantly greater hair follicle neogenesis than either agent alone, with new follicle counts exceeding vehicle control by over 2-fold (src-5, src-3, src-4, src-9, src-11, src-18). One profile cautions that because the amplified effect was seen with the combination, standalone topical use may be substantially less effective than the published combination protocol (src-9). Additional mouse work reports that PTD-DBM restored hair loss caused by PGD, overcame PGD suppression of neogenic hair growth, and alleviated DHT-induced hair loss (PubMed 36831222, src-15). On the wound-healing side, the 2015 study reported that co-treatment of skin wounds with PTD-DBM and valproic acid synergistically accelerated cutaneous wound healing in mice (src-18); a study (PubMed 36854308) reported HA-PG patches loaded with PTD-DBM and valproic acid inhibited scar formation, suppressed alpha-smooth muscle actin, induced stem-cell markers CD105 and Nestin, and induced collagen III (src-17); and one vendor profile cites an Adv Healthc Mater 2023 report that PTD-DBM delivered via adhesive hydrogel promoted regenerative, scar-free wound healing (src-13).

Human evidence and target relevance

One profile cites a 2023 PMC study confirming CXXC5 overexpression in androgenetic alopecia scalp biopsies, with other sources noting CXXC5 is increased in bald scalps, supporting target relevance in human disease (src-5, src-11). Beyond target relevance, human efficacy claims conflict. A tier-1 PubMed review states that PTD-DBM activates Wnt/beta-catenin by interfering with CXXC5 and shows clinical efficacy as a peptide therapeutic for hair follicle growth, with potential as a more effective option than finasteride and minoxidil (src-16). One article states PTD-DBM is the only injectable peptide with a published human study directly showing increased hair follicle count, but describes that study (Choi et al., 2017, n=34) as small and unregistered (src-12), and a tier-4 vendor profile claims a Phase 1/2 trial (n=40, 24 weeks) demonstrated a +28.4% hair count increase versus baseline with no serious adverse events (src-4). Against these, multiple sources state that as of 2026 no completed peer-reviewed human clinical trials or RCTs of PTD-DBM have been published, all direct efficacy data coming from mouse models and in vitro dermal papilla studies (src-1, src-3, src-5, src-6, src-9, src-10). Separately, a tier-2 review notes that a phase 2A trial of PP405 — a different hair-follicle-stem-cell-activating peptide, not PTD-DBM — demonstrated statistically significant hair regrowth in eight weeks among 78 patients (src-14).

Positioning

One vendor guide notes PTD-DBM is described as unique in targeting Wnt/beta-catenin via CXXC5 inhibition, a mechanism distinct from minoxidil (blood flow), finasteride (DHT blocking), and GHK-Cu (gene-expression modulation), noting minoxidil produces roughly 40% moderate responders (src-9, src-12).

What the research shows

162 findings extracted from the 18 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 2 human trial findings, 4 human study findings, 16 animal findings, 2 in vitro findings, 8 expert opinion findings and 2 theoretical findings.

  • human trialA phase 2A trial of PP405, a peptide that activates hair follicle stem cells, demonstrated statistically significant hair regrowth in just eight weeks among 78 patients2

  • human trialPhase 1/2 clinical trial (n=40, 24 weeks) demonstrated +28.4% hair count increase vs baseline with no serious adverse events11

  • human studyPTD-DBM shows clinical efficacy as a peptide therapeutic for hair follicle growth1

  • human studyA 2023 PMC study confirmed CXXC5 overexpression in androgenetic alopecia scalp biopsies, supporting target relevance in human disease6

  • human studyCXXC5 protein levels were reduced in epidermal keratinocytes and dermal fibroblasts of acute wounds in humans9

  • human studyPTD-DBM is the only injectable peptide with a published human study directly showing increased hair follicle count10

  • animalResearch shows it can stimulate new hair growth and increase hair follicle size4

  • animalLee 2017 showed that PTD-DBM stimulated hair regrowth and wound-induced hair neogenesis in mouse models4

Show the remaining 26

  • animalCombined with valproic acid (a separate Wnt activator), the effect was amplified4

  • animalTopical application of PTD-DBM to shaved mouse skin induced formation of new hair follicles from epidermal and dermal progenitor cells5

  • animalPTD-DBM-treated skin developed histologically confirmed hair follicles with proper dermal papilla organization, inner and outer root sheaths, and hair fiber production5

  • animalTopical PTD-DBM alone produced visible hair regrowth in C57BL/6 mice at levels comparable to minoxidil6

  • animalCombined PTD-DBM plus valproic acid produced significantly greater hair follicle neogenesis than either agent alone, with new hair follicle counts exceeding vehicle control by over 2-fold6

  • animalHA-PG patches loaded with PTD-DBM and valproic acid (VPA) significantly inhibited scar formation during wound healing in mice7

  • animalHair loss by PGD was restored by treatment of PTD-DBM8

  • animalSuppression of neogenic hair growth by PGD was overcome by PTD-DBM treatment8

  • animalCXXC5(-/-) mice exhibited accelerated cutaneous wound healing9

  • animalCXXC5(-/-) mice exhibited enhanced keratin 14 and collagen synthesis9

  • animalIn mouse models, topical PTD-DBM stimulated hair regrowth and wound-induced hair neogenesis, with effects amplified by valproic acid12

  • animalThe foundational 2017 mouse study demonstrated visible hair regrowth and de novo follicle neogenesis14

  • animalAll direct efficacy data comes from mouse models and in vitro dermal papilla cell studies14

  • animalIn preclinical models, topical PTD-DBM application activates hair follicle stem cells and induces anagen (growth phase) re-entry in telogen-phase follicles15

  • in vitroPTD-DBM treatment of cultured human dermal papilla cells restored alkaline phosphatase activity and increased expression of versican, beta-catenin, and LEF-15

  • in vitroPTD-DBM delivered via adhesive hydrogel activates Wnt/beta-catenin signalling to promote regenerative, scar-free wound healing superior to conventional treatments13

  • expert opinionAs of 2026, no human clinical trials have been published6

  • expert opinionPTD-DBM study (Choi et al., 2017) was small and unregistered10

  • expert opinionGHK-Cu has the broadest skin-science publication record but human injectable RCT data for hair specifically is absent10

  • expert opinionEvidence is preclinical, with no completed human trials and no established human pharmacokinetics12

  • expert opinionEnhancing beta-catenin signaling in dermal papilla cells produces faster and denser hair growth16

  • expert opinionCurrent evidence is primarily preclinical and mechanistic, not a basis for human-use instructions or therapeutic claims17

  • expert opinionCurrent evidence is primarily preclinical and mechanistic, not a basis for human-use instructions or therapeutic claims18

  • expert opinionMuch of the evidence is preclinical, cell-based or animal-model focused18

  • theoreticalAs of 2026, no published human RCT of PTD-DBM exists4

  • theoreticalAll published efficacy is in mouse models. There is no human RCT of PTD-DBM for androgenetic alopecia or any other hair-loss indication as of 20264

How it works

Based on 2 human study findings, 9 animal findings, 7 in vitro findings, 28 expert opinion findings and 36 theoretical findings.

  • human studyPTD-DBM activates the Wnt/β-catenin pathway by interfering with CXXC5, a negative regulator that inhibits pathway activation1

  • human studyCXXC5 is increased in expression in bald scalps3

  • animalLee 2017 showed that PTD-DBM disrupts CXXC5-Dishevelled binding and thereby restores Wnt/β-catenin signaling4

  • animalHA-PG patches with PTD-DBM and/or VPA inhibit the expression of differentiated cell markers such as α-smooth muscle actin (α-SMA)7

  • animalHA-PG patches with PTD-DBM and/or VPA induce the expression of stem cell markers such as CD105 and Nestin7

  • animalCollagen III is critically induced by the HA-PG patches with PTD-DBM and/or VPA7

  • animalPTD-DBM is a peptide activating the Wnt/β-catenin pathway via interference with the Dishevelled (Dvl) binding function of CXXC58

  • animalBPC-157 promotes angiogenesis via VEGF and NO pathways10

Show the remaining 74

  • animalCXXC5 binds directly to Dishevelled (Dvl), a key scaffolding protein in canonical Wnt signaling, and this interaction suppresses downstream Wnt activity14

  • animalA 2015 Journal of Experimental Medicine study demonstrated that disrupting the CXXC5-Dvl interaction accelerated skin repair in mouse models14

  • animalA 2007 Nature paper by Ito, Cotsarelis, and colleagues demonstrated that Wnt signaling can produce entirely new follicles in adult mouse skin after wounding14

  • in vitroPTD-DBM is a peptide inhibiting the CXXC-type zinc finger protein 5 (CXXC5)-Dvl interaction7

  • in vitroCXXC5 serves as a negative feedback regulator of the Wnt/β-catenin pathway by interacting with the Dishevelled (Dvl) protein9

  • in vitroCXXC5 overexpression and silencing differentially regulated β-catenin, α-SMA, and collagen I in vitro, indicating a critical role in myofibroblast differentiation and collagen production9

  • in vitroPTD-DBM is a competitor peptide blocking CXXC5-Dvl interactions9

  • in vitroPTD-DBM disrupted the CXXC5-Dvl negative feedback loop and activated β-catenin and collagen production in vitro9

  • in vitroGHK-Cu upregulates VEGF and FGF-7 in lab models10

  • in vitroPTD-DBM peptide blocks CXXC5-Dvl interaction to restore Wnt signalling and accelerate wound closure and hair follicle regeneration13

  • expert opinionShort peptides that mimic intracellular signals exhibit diverse biological effects and have emerged as a promising approach for stimulating hair regrowth2

  • expert opinionVPA is used as a drug for bipolar disorder and activates the Wnt/β-catenin pathway by inhibition of GSK3β3

  • expert opinionPTD-DBM is unique in targeting Wnt/β-catenin via CXXC5 inhibition — a fundamentally different mechanism from minoxidil (blood flow), finasteride (DHT blocking), or GHK-Cu (gene expression modulation)4

  • expert opinionPTD-DBM is a chimeric synthetic peptide comprising a protein transduction domain (PTD) derived from HIV-1 TAT fused to a Dishevelled-binding motif (DBM) originating from the CXXC5 protein11

  • expert opinionThe PTD enables cell membrane penetration via macropinocytosis and electrostatic interaction with anionic phospholipid bilayers, bypassing receptor-mediated endocytosis11

  • expert opinionIntracellularly, the DBM competitively inhibits the CXXC5–Dishevelled (Dvl) PDZ domain protein–protein interaction11

  • expert opinionCXXC5 normally functions as a negative feedback regulator of canonical Wnt/β-catenin signaling by binding the Dvl PDZ domain and suppressing downstream signal propagation11

  • expert opinionBy competitively displacing CXXC5, PTD-DBM relieves this inhibition and stabilizes cytoplasmic β-catenin which translocates to the nucleus and engages TCF/LEF transcription factors, driving Wnt target gene expression11

  • expert opinionIn androgenetic alopecia, the DHT→PGD2→CXXC5 axis upregulates CXXC5, suppressing Wnt signaling and arresting follicle cycling; PTD-DBM reverses this by restoring Dvl-mediated signaling11

  • expert opinionPTD-DBM combined with Valproic Acid activates Wnt signalling pathways to stimulate hair follicle stem cell regeneration and transition follicles from telogen to anagen phase13

  • expert opinionPTD-DBM operates through sophisticated pathways to promote hair follicle regeneration and growth involving modulating key signaling pathways involved in hair follicle cycling and development13

  • expert opinionThe peptide complex, enhanced by Valproic Acid, influences cellular processes crucial for hair growth, including follicle stem cell activation and proliferation13

  • expert opinionPTD-DBM helps create an optimal environment for hair growth by supporting blood circulation to the scalp and regulating local growth factors13

  • expert opinionPTD-DBM is a synthetic peptide designed to block the CXXC5-Dvl interaction and disinhibit Wnt/beta-catenin signaling in hair follicles14

  • expert opinionIn 2015, Kim and colleagues in the Choi lab identified CXXC5 as a negative-feedback regulator of the Wnt/beta-catenin pathway14

  • expert opinionPTD refers to the protein transduction domain, which enables cellular entry across the stratum corneum; DBM refers to the Dishevelled-binding motif, the portion that physically competes with CXXC5 for the Dvl PDZ domain14

  • expert opinionWnt/beta-catenin signaling is the dominant molecular pathway governing hair follicle development, regeneration, and cycling14

  • expert opinionPTD-DBM is a fusion peptide combining a protein transduction domain (PTD) with a Dishevelled-binding motif (DBM) that activates the Wnt/β-catenin signaling pathway intracellularly15

  • expert opinionThe PTD enables cell membrane penetration without receptor binding15

  • expert opinionThe DBM fragment stabilizes β-catenin by disrupting the Axin-Dishevelled interaction15

  • expert opinionPTD-DBM bypasses surface receptors entirely and delivers Wnt pathway activation directly inside the cell15

  • expert opinionPTD-DBM targets the Wnt/β-catenin pathway via Axin-Dvl disruption15

  • expert opinionCXXC5 binds to Dishevelled, and when that binding happens, it shuts down the Wnt/beta-catenin signaling pathway16

  • expert opinionPTD-DBM works by inserting itself between CXXC5 and Dishevelled, physically preventing the interaction that suppresses hair growth16

  • expert opinionWhen CXXC5 cannot bind Dishevelled, the Wnt pathway stays active16

  • expert opinionThe Wnt/beta-catenin pathway controls whether hair follicles grow, rest, or die16

  • expert opinionInactivation of beta-catenin causes dramatically reduced proliferation of hair progenitor cells and premature entry into catagen16

  • expert opinionCXXC5 acts as a negative feedback regulator16

  • theoreticalPTD-DBM is a man-made peptide which interacts with the mechanism of hair loss linked endogenous protein, CXXC5, which is a negative feedback regulator of the Wnt/β-catenin pathway3

  • theoreticalPTD-DBM is a peptide activating the Wnt/β-catenin signaling pathway functioning via interference of the binding of CXXC5 to Dishevelled (Dvl)3

  • theoreticalCXXC5 acts as a negative regulator for the Wnt/β-catenin pathway involved in hair regeneration and wound healing3

  • theoreticalWhen CXXC5 binds with the Dvl protein it suppresses hair regrowth and hair follicle neogenesis3

  • theoreticalPTD-DBM interferes with the CXXC5-Dvl protein-protein interaction (PPI)3

  • theoreticalPTD-DBM is a cell-penetrating peptide that promotes hair growth by inhibiting CXXC5, a negative regulator of the Wnt/β-catenin signaling pathway4

  • theoreticalBy blocking CXXC5-Dishevelled interaction, it activates Wnt signaling which is essential for hair follicle development and cycling4

  • theoreticalPTD-DBM is a cell-permeable peptide that activates the Wnt/beta-catenin signaling pathway by binding the Dishevelled protein5

  • theoreticalThe protein transduction domain (derived from HIV-TAT) enables the peptide to cross cell membranes without requiring receptor-mediated endocytosis5

  • theoreticalPTD-DBM reaches intracellular targets in dermal papilla cells, outer root sheath keratinocytes, and hair follicle stem cells in the bulge region5

  • theoreticalThe DBM motif binds the DIX domain of Dishevelled proteins (Dvl1, Dvl2, Dvl3)5

  • theoreticalThis interaction promotes Dvl polymerization and enhances its ability to recruit Axin away from the beta-catenin destruction complex5

  • theoreticalStabilized beta-catenin accumulates and enters the nucleus, where it forms complexes with TCF/LEF transcription factors to activate Wnt target genes5

  • theoreticalPTD-DBM contains a protein transduction domain (PTD) fused to a dishevelled-binding motif (DBM)6

  • theoreticalPTD-DBM functions by disrupting the inhibitory CXXC5–Dishevelled protein interaction to reactivate Wnt/β-catenin signaling in hair follicles6

  • theoreticalPTD-DBM contains an eight-arginine PTD sequence (RRRRRRRR) that enables membrane transduction and penetration into follicular cells6

  • theoreticalPTD-DBM is fused to a DBM segment (RKTGHQICKFRK) that competitively displaces CXXC5 from Dvl6

  • theoreticalIGF-1 LR3 has clear biological rationale through the PI3K/Akt pathway10

  • theoreticalPTD-DBM is a cell-penetrating peptide designed to inhibit CXXC-type zinc finger protein 5 (CXXC5), a negative regulator of the Wnt/beta-catenin signaling pathway10

  • theoreticalPTD-DBM is a synthetic cell-penetrating peptide that reactivates Wnt/beta-catenin signaling in hair follicles12

  • theoreticalAn octa-arginine transduction domain carries a CXXC5-derived Dishevelled-binding motif into cells, where it out-competes CXXC5 for Dishevelled and releases CXXC5's brake on the pathway, driving hair-follicle stem-cell activation and follicle neogenesis12

  • theoreticalPTD-DBM is an engineered research peptide designed to interfere with the interaction between CXXC5 and Dishevelled, a protein-protein interaction that negatively regulates Wnt/β-catenin signaling17

  • theoreticalCXXC5 acts like a brake on Wnt/β-catenin signaling17

  • theoreticalPTD-DBM is designed to interfere with the CXXC5-Dishevelled interaction, which may reduce that brake in experimental models and allow Wnt pathway activity to increase17

  • theoreticalPTD-DBM is built from a protein transduction domain, which supports cellular entry in experimental systems, and a Dishevelled-binding motif, which is designed to compete with CXXC5 for interaction with Dishevelled17

  • theoreticalCXXC5 is a negative regulator that can suppress Wnt/β-catenin pathway activity17

  • theoreticalCXXC5 binding to Dvl can suppress pathway activity in experimental models17

  • theoreticalBy interfering with that interaction, PTD-DBM is studied as a Wnt/β-catenin pathway activator17

  • theoreticalPTD-DBM stands for protein transduction domain-fused Dishevelled-binding motif18

  • theoreticalPTD-DBM is designed to disrupt the binding of CXXC5 to Dishevelled, thereby relieving a negative regulator of Wnt/β-catenin signaling18

  • theoreticalCXXC5 acts like a brake on Wnt/β-catenin signaling18

  • theoreticalPTD-DBM is designed to interfere with the CXXC5-Dishevelled interaction, which may reduce that brake in experimental models and allow Wnt pathway activity to increase18

  • theoreticalPTD-DBM is an engineered peptide built from a protein transduction domain, which supports cellular entry in experimental systems, and a Dishevelled-binding motif, which is designed to compete with CXXC5 for interaction with Dishevelled18

  • theoreticalCXXC5 is described as a negative regulator of Wnt/β-catenin signaling pathway18

  • theoreticalCXXC5 binding to Dvl can suppress pathway activity in experimental models18

  • theoreticalBy interfering with that interaction, PTD-DBM is studied as a Wnt/β-catenin pathway activator18

Dosing

Based on 1 animal finding and 7 expert opinion findings.

  • animalUsed in rodent studies as topical solution, typically 1–5 mg/mL dissolved in DMSO/PBS6

  • expert opinionMicroneedling sessions (1-2x/week) significantly enhance results4

  • expert opinionOptimal Timing morning11

  • expert opinionTypical dose is 0.5-1 mg/mL topical to scalp (~250-1000 mcg per application)12

  • expert opinionCommonly applied once daily to the scalp12

  • expert opinionApply as directed to affected areas, once daily, preferably in the evening13

  • expert opinionDuration of 3-6 months for optimal results13

  • expert opinionReconstitution is via topical vehicle (DMSO or gel base)15

How the body handles it

Based on 1 expert opinion finding and 2 theoretical findings.

  • expert opinionEstimated 24h Plasma Clearance: 6h (t½ ~50%), 12h (25%), 24h (<5%)11

  • theoreticalPoly-arginine cell-penetrating peptides are rapidly proteolyzed with plasma half-life of approximately minutes12

  • theoreticalTopical action is governed by local follicular penetration rather than a systemic half-life12

Safety and side effects

Based on 8 expert opinion findings.

  • expert opinionIGF-1 LR3 carries systemic risks including hypoglycemia and potential tumor promotion10

  • expert opinionEndotoxin testing (LAL assay, below 1 EU/mg) on a COA is non-negotiable for any injectable peptide10

  • expert opinionPTD-DBM is not FDA- or EMA-approved12

  • expert opinionLyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy12

  • expert opinionPTD-DBM + Valproic Acid requires careful medical supervision and individualized dosing13

  • expert opinionAs of April 2026 no completed, peer-reviewed human clinical trials of PTD-DBM exist, and the compound has no FDA approval or IND filing14

  • expert opinionNot FDA-approved for human use as of April 202614

  • expert opinionStability is limited with data to prepare fresh for optimal activity15

What people use it for

Based on 10 animal findings, 7 expert opinion findings, 1 anecdotal finding and 3 theoretical findings.

  • animalApplication of the peptide to bald laboratory mice resulted in new hair follicle growth3

  • animalBy topical application, the PTD-DBM promotes the formation of new hair follicles and prevents hair loss3

  • animalCombinatory treatment of PTD-DBM with valproic acid (VPA), the activator of Wnt/β-catenin pathway, further induce hair re-growth as well as wound-induced hair neogenesis (WIHN)3

  • animalLee 2017 showed amplified effect when PTD-DBM was combined with valproic acid (a Wnt activator). Standalone topical use may be substantially less effective than the published combination protocol4

  • animalPTD-DBM promotes hair follicle neogenesis and regeneration5

  • animalPTD-DBM has been studied topically and in combination with valproic acid for androgenetic alopecia and wound-induced hair neogenesis in rodent models6

  • animalPTD-DBM in combination with HA-PG patches promoted regenerative wound healing in mice7

  • animalPTD-DBM treatment alleviates DHT-induced hair loss8

Show the remaining 13

  • animalCo-treatment of skin wounds with PTD-DBM and valproic acid (VPA) synergistically accelerated cutaneous wound healing in mice9

  • animalSynergistic co-treatment with valproic acid (GSK-3β inhibitor) further amplifies β-catenin stabilization, producing additive wound healing and hair neogenesis in murine models11

  • expert opinionPTD-DBM demonstrates potential as a more effective treatment option than finasteride and minoxidil1

  • expert opinionBy combining different formulations and nanosystems, the limitations of short peptides can be effectively addressed2

  • expert opinionHair growth is slow — expect 3-6 months minimum for visible improvements4

  • expert opinionPTD-DBM is sold for research and cosmetic use only12

  • expert opinionPTD-DBM is prescribed for hair regeneration protocols targeting follicle stem cell activation, particularly for patients with androgenetic alopecia or early-stage hair thinning13

  • expert opinionNot legally marketed for human use in the United States14

  • expert opinionPTD-DBM is designed to target CXXC5 inhibition for hair restoration16

  • anecdotalPTD-DBM is often used topically or via microneedling for androgenetic alopecia and hair thinning4

  • theoreticalPTD-DBM has been studied in hair regrowth, wound-induced hair follicle neogenesis, DHT-PGD2-CXXC5 pathway research and regenerative wound healing models17

  • theoreticalIn published preclinical models, PTD-DBM has been studied in hair regrowth, wound-induced hair follicle neogenesis, DHT-PGD2-CXXC5 pathway research and regenerative wound healing models18

  • theoreticalPTD-DBM has been discussed most often in hair follicle, wound-induced hair neogenesis, DHT-PGD2-CXXC5 pathway and regenerative wound-healing research18

Other findings

Based on 5 expert opinion findings and 1 theoretical finding.

  • expert opinionPTD-DBM is a synthetic 25-amino-acid research peptide developed by Professor Kang-Yell Choi's lab at Yonsei University6

  • expert opinionMost consumer-market peptide sellers do not provide endotoxin testing10

  • expert opinionPTD-DBM was developed by the Choi laboratory at Yonsei University in South Korea14

  • expert opinionPTD-DBM was reported publicly in a 2017 paper in the Journal of Investigative Dermatology14

  • expert opinionPTD-DBM is a fusion peptide with molecular weight ~2,500 Da15

  • theoreticalPTD-DBM stands for protein transduction domain-fused Dishevelled-binding motif17

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Efficacy evidence is overwhelmingly preclinical (mouse and in vitro)

Direct efficacy data for hair regrowth and wound healing comes from mouse models and cultured dermal papilla cells; human pharmacokinetics are not established and dosing figures are extrapolated or vendor-derived rather than clinically validated.

Other

Standalone efficacy may be weaker than the studied combination

Much of the strongest preclinical hair-neogenesis and wound-healing data used PTD-DBM combined with valproic acid; one source (PTD-DBM: How It Works, Mechanism & Evidence (2026)) cautions standalone topical use may be substantially less effective than the published combination protocol.

Other

PP405 phase 2A trial data is about a different peptide, not PTD-DBM

The tier-2 review (Overview of Short Peptides for Hair Loss - PMC) reports an eight-week phase 2A trial in 78 patients, but this is for PP405, a separate hair-follicle-stem-cell-activating peptide, not PTD-DBM.

What you may have heard

Although one review describes PTD-DBM as showing 'clinical efficacy' and as potentially better than finasteride and minoxidil, no completed human trial actually backs that up.

A 2025 narrative review of hair-regrowth strategies (PubMed 40497955) states that peptides such as PTD-DBM show 'clinical efficacy' and have 'potential as more effective treatment options than existing solutions such as finasteride and minoxidil.' This is a forward-looking summary in a review article, not a report of a human trial result. All direct efficacy evidence for PTD-DBM comes from mouse models and cultured dermal papilla cells, and multiple sources note that as of 2026 no completed, peer-reviewed human clinical trial has been published. The review's 'clinical efficacy' wording should not be read as proof of a human benefit, and the 'more effective than finasteride and minoxidil' comparison has never been tested head-to-head in people.

Inconsistency

Descriptions of exactly how PTD-DBM releases the brake on Wnt signaling do not agree with one another.

PTD-DBM is built from a fragment of CXXC5, the protein that normally slows Wnt/beta-catenin signaling by binding a scaffolding protein called Dishevelled (Dvl). The established account, from the Choi lab's original work, is that PTD-DBM competes with CXXC5 for the same site on Dvl (the PDZ domain), displacing the natural brake. One vendor profile instead describes the peptide binding a different part of Dvl (the DIX domain) and promoting Dvl polymerization — a mechanistically distinct picture that conflicts with, rather than supports, the competition model. Because CXXC5 is itself a PDZ-domain-binding partner of Dvl, a CXXC5-derived decoy would be expected to act at the PDZ domain; the DIX-polymerization description appears to be a garbled account and is not supported by the primary literature.

Safety and side effects

Regulatory and safety status

Multiple sources state that PTD-DBM is not FDA- or EMA-approved, has no IND filing as of April 2026, is not legally marketed for human use in the United States, and is sold for research and cosmetic use only (src-1, src-3). One dosage profile states that lyophilized peptides are investigational chemical compounds not approved for human consumption, diagnosis, or therapy (src-3).

Adverse events reported

Direct human safety data are essentially absent. The only adverse-event claim among the sources is from a tier-4 vendor profile, which reports "no serious adverse events" in a claimed Phase 1/2 trial (n=40, 24 weeks) (src-4) — a claim that conflicts with the consensus that no completed peer-reviewed human trials have been published (src-1, src-3, src-5, src-6, src-9, src-10). No systematic human tolerability or long-term safety profile is established in the provided sources.

Quality and injectable-use caution

One article states that endotoxin testing (LAL assay, below 1 EU/mg) on a certificate of analysis is essential for any injectable peptide, and that most consumer-market peptide sellers do not provide endotoxin testing (src-12).

Combination caution

Much of the strongest preclinical hair-neogenesis and wound-healing data used PTD-DBM combined with valproic acid; one source cautions that standalone topical use may be substantially less effective than the published combination protocol (src-9). One vendor profile states that PTD-DBM combined with valproic acid, used in hair-regeneration protocols, requires careful medical supervision (src-13). Note that valproic acid is separately described as a drug used for bipolar disorder that inhibits GSK3beta (src-11).

Evidence limitation

Efficacy and safety inferences rest overwhelmingly on mouse and in vitro data; human pharmacokinetics are not established, and dosing figures are extrapolated or vendor-derived rather than clinically validated.

Reconstitution and handling

Dosing

No dose has been established for this compound. No regulatory label exists for PTD-DBM — it is not FDA- or EMA-approved and has no IND filing as of April 2026 (src-1, src-3) — so the figures below are what sources report, not guidance. Direct efficacy evidence is preclinical, and dosing figures are extrapolated or vendor-derived.

Topical figures sources report

  • One dosage profile suggests a typical topical dose of 0.5–1 mg/mL applied to the scalp (~250–1000 mcg per application), commonly once daily (src-3).
  • Rodent studies are described by vendor material as typically using 1–5 mg/mL dissolved in DMSO/PBS (src-2, src-5, src-8).
  • Community and vendor sources report PTD-DBM is often applied topically or via microneedling for androgenetic alopecia and hair thinning, with 1–2 microneedling sessions per week said to enhance results (src-3, src-9).
  • One vendor source recommends applying once daily, preferably in the evening, while another suggests morning timing, with 3–6 months typically described before visible improvements (src-3, src-4, src-9, src-13).
  • One vendor profile describes a valproic-acid combination over a 3–6 month course, requiring careful medical supervision (src-13).

Reconstitution

These are container calculations reported by vendor/dosage sources, not dose recommendations:

  • Vendor dosing material describes reconstitution via a topical vehicle such as DMSO or a gel base (src-2, src-5, src-8).
  • One dosage guide lists a 5 mg vial reconstituted with 2.5 mL bacteriostatic water to a 2 mg/mL concentration, giving 20 mcg (0.0200 mg) per U-100 insulin-syringe unit (src-3, src-8).
  • One profile describes a 5 mg vial reconstituted with 2 mL bacteriostatic water yielding 2,500 mcg/mL and about 20 doses per vial (src-8).

Storage

Vendor storage guidance advises that PTD-DBM has limited stability and should be prepared fresh, stored refrigerated at 2–8°C or frozen at −20°C, with a reconstituted-solution shelf life of about 2–4 weeks (one source says 30 days) (src-2, src-3, src-8).

Quality note

One article states that for any injectable peptide, endotoxin testing (LAL assay, below 1 EU/mg) on a certificate of analysis is essential, and that most consumer-market sellers do not provide it (src-12).

Sources

Ordered by evidence quality — the strongest first.

  1. Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  2. Overview of Short Peptides for Hair Loss - PMC(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  3. PTD-DBM - Wikipedia(opens in a new tab)
    Tier 2Web · en.wikipedia.org
  4. PTD-DBM: How It Works, Mechanism & Evidence (2026)(opens in a new tab)
    Tier 2Web · thepeptidecatalog.com
  5. PTD-DBM: Research Profile, Mechanism & Protocols | PepGuide | PepGuide(opens in a new tab)
    Tier 2Web · pepguide.io
  6. PTD-DBM: Wnt Pathway Hair Peptide Research Guide | PeptaHub(opens in a new tab)
    Tier 2Web · peptahub.com · 2026
  7. Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  8. CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  9. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2015
  10. Best Injectable Peptides for Hair Growth: Evidence-Ranked Guide | FormBlends(opens in a new tab)
    Tier 3Web · formblends.com
  11. PTD-DBM - Neemio(opens in a new tab)
    Tier 3Web · neemio.com
  12. PTD-DBM Dosage Chart, Schedule & Reconstitution Protocol(opens in a new tab)
    Tier 3Web · peptidedosage.org
  13. PTD-DBM Thailand | Clinical Consultation(opens in a new tab)
    Tier 3Web · peptidesthailand.com
  14. PTD-DBM: A CXXC5-Dishevelled Disrupting Peptide(opens in a new tab)
    Tier 3Web · superpower.com
  15. PTD-DBM: Research Guide — Dosing, Half-Life & Protocols | Lumen Peppers(opens in a new tab)
    Tier 3Web · lumenpeppers.com · 2026
  16. PTD-DBM peptide: the complete guide to CXXC5 inhibition for hair ...(opens in a new tab)
    Tier 3Web · seekpeptides.com · 2026
  17. PTD-DBM Research Guide | CXXC5, Wnt Signaling & Hair Follicle Research(opens in a new tab)
    Tier 4Web · luxaralabs.com
  18. PTD-DBM Research Guide | CXXC5, Wnt Signaling & Hair Follicle Research(opens in a new tab)
    Tier 4Web · luxaralabs.com · 2026